Skip to main content

Chimeric Antigen Receptor T Cell Therapies For Cancer

In Order to Read Online or Download Chimeric Antigen Receptor T Cell Therapies For Cancer Full eBooks in PDF, EPUB, Tuebl and Mobi you need to create a Free account. Get any books you like and read everywhere you want. Fast Download Speed ~ Commercial & Ad Free. We cannot guarantee that every book is in the library!

Chimeric Antigen Receptor T Cell Therapies for Cancer E Book

Chimeric Antigen Receptor T Cell Therapies for Cancer E Book Book
Author : Daniel W. Lee,Nirali N. Shah
Publisher : Elsevier Health Sciences
Release : 2019-11-30
ISBN : 0323755976
Language : En, Es, Fr & De

GET BOOK

Book Description :

From patient referral to post-therapy management, Chimeric Antigen Receptor (CAR) T-Cell Therapies for Cancer: A Practical Guide presents a comprehensive view of CAR modified T-cells in a concise and practical format. Providing authoritative guidance on the implementation and management of CAR T-cell therapy from Drs. Daniel W. Lee and Nirali N. Shah, this clinical resource keeps you up to date on the latest developments in this rapidly evolving area. Covers all clinical aspects, including patient referral, toxicities management, comorbidities, bridging therapy, post-CAR monitoring, and multidisciplinary approaches to supportive care. Includes key topics on associated toxicities such as predictive biomarkers, infections, and multidisciplinary approaches to supportive care. Presents current knowledge on FDA approved CAR T-cell products as well as developments on the horizon. Editors and authors represent leading investigators in academia and worldwide pioneers of CAR therapy.

Fast Facts CAR T Cell Therapy

Fast Facts  CAR T Cell Therapy Book
Author : R.J. Buka,A.J. Kansagra
Publisher : Karger Medical and Scientific Publishers
Release : 2021-01-26
ISBN : 3318067423
Language : En, Es, Fr & De

GET BOOK

Book Description :

Chimeric antigen receptor (CAR) T cells are genetically engineered immune cells that can seek out and destroy cancer cells. The results from their use in cancer immunotherapy have been very promising, but treatment is often associated with frequent, serious short-term toxicities. 'Fast Facts: CAR-T Therapy' explains what CAR T cells are and how they were developed, discusses the results of clinical trials and the management of toxicities, and outlines future improvements and applications. It is ideal reading for any healthcare professional wanting to know more about this exciting therapeutic field. Table of Contents: • CAR T cells • Clinical application • Practical aspects • Future directions

Part I Understanding Cancer Immunotherapy A brief Review Part II What is Chimeric Antigen Receptor CAR T Cell Therapy An Emerging Cancer Treatment Modality

Part I  Understanding Cancer Immunotherapy  A brief Review  Part II      What is Chimeric Antigen Receptor  CAR T Cell Therapy  An Emerging Cancer Treatment Modality  Book
Author : Dr. Hakim Saboowala
Publisher : Dr.Hakim Saboowala
Release : 2020-05-04
ISBN : 0987650XXX
Language : En, Es, Fr & De

GET BOOK

Book Description :

Part I- Understanding Cancer Immunotherapy: A brief Review. Immunotherapy, also called biologic therapy, is a type of cancer treatment that boosts the body's natural defenses to fight cancer. It uses substances made by the body or in a laboratory to improve or restore immune system function. Immunotherapy may work by: Stopping or slowing the growth of cancer cells Stopping cancer from spreading to other parts of the body Helping the immune system work better at destroying cancer cells There are several types of immunotherapy, including: Monoclonal antibodies and tumor-agnostic therapies Non-specific immunotherapies Oncolytic virus therapy T-cell therapy Cancer vaccines Part II- “What is Chimeric Antigen Receptor (CAR) T- Cell Therapy?” An Emerging Cancer Treatment Modality. Chimeric antigen receptor (CAR) T-cell therapy is an emerging cancer treatment modality in which the patients’ own immune cells are collected, genetically engineered to recognize a tumor-related target, expanded in vitro, and then reinfused to produce responses and prevent progression in a variety of malignancies (ie, adoptive cell transfer) Several types of adoptive cell transfer(ACT) are under investigation, but CAR T-cell therapy is the first to enter clinical practice. Like other technologies, CAR-T cell therapy has undergone a long development process in the past. Chimeric antigen receptor- (CAR-) T cell therapy is one of the most recent innovative immunotherapies and is rapidly evolving. At present, CAR-T cell therapy is developing rapidly, and many clinical trials have been established on a global scale, which has great commercial potential. I have endeavored to compile this E- Booklet into Two Parts i.e. Part I & Part II for better understanding of Chimeric antigen receptor (CAR) T-cell therapy, an emerging cancer treatment modality. In Part I, an effort has been made to describe Cancer Immunotherapy briefly whereas in Part II know about of CAR T-Cell Therapy-the first to enter clinical practice- has been embodied. Further it is attempted to describe toxicity of CAR-T cell therapy briefly and future development and opportunities for immunotherapy. …Dr. H. K. Saboowala. M.B.(Bom) .M.R.S.H.(London)

Chimeric Antigen Receptor T Cell Therapies for Cancer

Chimeric Antigen Receptor T Cell Therapies for Cancer Book
Author : Daniel W. Lee,Nirali N. Shah, M.D.
Publisher : Elsevier
Release : 2019-12-02
ISBN : 9780323661812
Language : En, Es, Fr & De

GET BOOK

Book Description :

From patient referral to post-therapy management, Chimeric Antigen Receptor (CAR) T-Cell Therapies for Cancer: A Practical Guide presents a comprehensive view of CAR modified T-cells in a concise and practical format. Providing authoritative guidance on the implementation and management of CAR T-cell therapy from Drs. Daniel W. Lee and Nirali N. Shah, this clinical resource keeps you up to date on the latest developments in this rapidly evolving area. Covers all clinical aspects, including patient referral, toxicities management, comorbidities, bridging therapy, post-CAR monitoring, and multidisciplinary approaches to supportive care. Includes key topics on associated toxicities such as predictive biomarkers, infections, and multidisciplinary approaches to supportive care. Presents current knowledge on FDA approved CAR T-cell products as well as developments on the horizon. Editors and authors represent leading investigators in academia and worldwide pioneers of CAR therapy.

Cellular Therapies in Cancer

Cellular Therapies in Cancer Book
Author : Katy Rezvani,Rohtesh S. Mehta
Publisher : Frontiers Media SA
Release : 2020-01-16
ISBN : 2889633780
Language : En, Es, Fr & De

GET BOOK

Book Description :

Download Cellular Therapies in Cancer book written by Katy Rezvani,Rohtesh S. Mehta, available in PDF, EPUB, and Kindle, or read full book online anywhere and anytime. Compatible with any devices.

CAR T Cell Therapies for Non Hematopoietic Malignancies Taking Off The Training Wheels

CAR T Cell Therapies for Non Hematopoietic Malignancies  Taking Off The Training Wheels Book
Author : Avery Dexter Posey, Jr.,John - Maher,Marcela V. Maus
Publisher : Frontiers Media SA
Release : 2020-04-24
ISBN : 2889636879
Language : En, Es, Fr & De

GET BOOK

Book Description :

Chimeric antigen receptor (CAR) T cell therapies for leukemia (e.g. tisagenlecleucel) and lymphoma (e.g. axicabtagene ciloleucel) have recently received regulatory approval in the United States. Phase I/II trials have demonstrated complete remission of refractory or relapsed tumors in 50% - 94% patients. However, the clinical successes of engineered T cells for the treatment of solid malignancies have thus far been few and far between. Furthermore, several instances of severe and lethal toxicities have arisen due to on-target, off-tumor recognition of antigen by T cell products. Recent advances in phase I trials for solid tumors, as well as in pre-clinical models, have revealed several variables that will be important to consider for the successful use of CAR-T cells in treating solid tumors. These variables include (i) regional versus systemic delivery; (ii) scFv versus ligand interactions; (iii) antigen loss versus escape; (iv) epitope spreading and (v) checkpoint expression on immune cells or tumor cells. Also, there remains outstanding mechanistic questions related to why differences exist in the persistence and tonic signaling of second-generation CD28 versus 4-1BB co-stimulated CAR-T cells. In addition, we are now learning the roles of lympho-depleting regimens (and associated toxicities) in modifying the persistence of engineered T cell therapies. A more comprehensive view of CAR-T cell strategies and important advances, both of pre-clinical and clinical evaluations, in solid tumors is necessary to drive these therapies forward.

Cellular Therapy Of Cancer Development Of Gene Therapy Based Approaches

Cellular Therapy Of Cancer  Development Of Gene Therapy Based Approaches Book
Author : Robert E Hawkins
Publisher : World Scientific
Release : 2014-05-05
ISBN : 9814618535
Language : En, Es, Fr & De

GET BOOK

Book Description :

Cancer research has progressed enormously in recent years. This review volume will address recent findings in the area of T-cell therapy for cancer, including use of tumour infiltrating lymphocytes (TILs) as a therapy for melanoma, choice of target antigens, advances in engineered receptors, methods of gene transfer to T cells, review of cell processing methods and clinical trial design. Written by leadings scientists in the field, this up-to-date review on cancer research will be an important reference source to the researchers and healthcare professionals in the field.

Basics of Chimeric Antigen Receptor CAR Immunotherapy

Basics of Chimeric Antigen Receptor  CAR  Immunotherapy Book
Author : Mumtaz Y. Balkhi
Publisher : Academic Press
Release : 2019-07-31
ISBN : 0128197471
Language : En, Es, Fr & De

GET BOOK

Book Description :

Basics of Chimeric Antigen Receptor (CAR) Immunotherapy presents the latest on how T cell adoptive immunotherapy has progressed in its ultimate goal of curing metastatic malignant cancers. Recent clinical data obtained with checkpoint receptor blockade inhibitors and chimeric antigen receptor (CAR) therapy has been especially promising, thus generating renewed hope that we may be on the verge of finally curing cancer. Over the years, huge progress has been made in controlling several stage IV metastasized cancers through the clinical application of checkpoint receptor inhibitory drugs and CAR-Therapy that has seen unprecedented interest in the immunotherapy field. Presents the first book to provide a basic understanding of chimeric antigen receptor (CARs) design, production and clinical application protocols Provides unique authority as the editor has worked directly with CARs Discusses the challenges encountered in actual clinical trials and how these challenges can be overcome Includes a full chapter on various challenges researchers should expect to encounter in the CAR-therapy field

Fast Facts CAR T Cell Therapy

Fast Facts  CAR T Cell Therapy Book
Author : Richard J. Buka,Ankit J. Kansagra
Publisher : Karger Medical and Scientific Publishers
Release : 2021-02-28
ISBN : 3318067415
Language : En, Es, Fr & De

GET BOOK

Book Description :

Chimeric antigen receptor (CAR) T cells are genetically engineered immune cells that can seek out and destroy cancer cells. The results from their use in cancer immunotherapy have been very promising, but treatment is often associated with frequent, serious short-term toxicities. 'Fast Facts: CAR-T Therapy' explains what CAR T cells are and how they were developed, discusses the results of clinical trials and the management of toxicities, and outlines future improvements and applications. It is ideal reading for any healthcare professional wanting to know more about this exciting therapeutic field. Table of Contents: • CAR T cells • Clinical application • Practical aspects • Future directions

Development of Biomaterials for Chimeric Antigen Receptor CAR T Cell Therapy

Development of Biomaterials for Chimeric Antigen Receptor  CAR  T Cell Therapy Book
Author : Brynn Riann Olden
Publisher : Unknown
Release : 2018
ISBN : 0987650XXX
Language : En, Es, Fr & De

GET BOOK

Book Description :

Chimeric antigen receptor (CAR) T cell therapy has emerged as an effective new cancer treatment that genetically reprograms a patient’s T cells to recognize an epitope specifically expressed on the surface of cancer cells and trigger cytotoxic action against those cancer cells. This therapy has been especially effective in the treatment of CD19+ hematologic malignancies. However, the manufacturing of these autologous cell therapies requires laborious processing steps that present multiple challenges and opportunities for innovation, described in Chapter 1. The current manufacturing system requires extensive use of biologic reagents including antibody-coated magnetic beads for manipulation and expansion, and retroviruses for genetic modification of ex vivo cultured T cells. In this work, three classes of synthetic biomaterials are developed to improve and study the ex vivo expansion and genetic modification of primary human T cells. In Chapter 2, we describe the development of cell-templated supported lipid bilayers as a platform for studying the effect of activation particle design on polyclonal T cell expansion and differentiation. Chapter 3 describes work towards identifying synthetic peptide and aptamer targeting ligands for T cell activation through library screening techniques. In Chapters 4 and 5, we report the use of cationic polymers of defined architecture for non-viral gene delivery to T cells and study the underlying barriers to improved gene delivery in T cells. The major findings from this work are summarized in Chapter 6 where we also make recommendations for future applications and directions of this work.

Current Immunotherapeutic Strategies in Cancer

Current Immunotherapeutic Strategies in Cancer Book
Author : Matthias Theobald
Publisher : Springer Nature
Release : 2019-08-31
ISBN : 3030237656
Language : En, Es, Fr & De

GET BOOK

Book Description :

This book offers a comprehensive review of recent advances in cancer immunotherapy, and explores the value and limitations of the most effective current therapeutic strategies and emerging treatment modalities. It discusses in detail the successes achieved using monoclonal antibodies (mAbs), including developments with regard to conjugated mAbs and also bispecific mAbs as novel treatment options for leukemia and solid tumors. It also examines the advances toward personalized immunotherapy, focusing on the effectiveness of adoptive cell therapy using genetically engineered T cells with tumor-associated antigen-specific T-cell receptors and chimeric antigen receptors, as well as the role of tailored vaccines based on the patient’s cancer mutanome. Further, it describes the impressive therapeutic results recently achieved with checkpoint inhibitors, and analyzes novel strategies to modulate the immunosuppressive tumor microenvironment. Written by leading international experts and providing up-to-date information on emerging strategies, such as oncolytic virus-based therapy, epigenetic therapy, and combination therapy, the book appeals to all those with an interest in immunotherapy as it comes of age.

Endogenous Leukocyte Activation by Chimeric Antigen Receptor T Cell Immunotherapy

Endogenous Leukocyte Activation by Chimeric Antigen Receptor T Cell Immunotherapy Book
Author : Paul Spear
Publisher : Unknown
Release : 2013
ISBN : 0987650XXX
Language : En, Es, Fr & De

GET BOOK

Book Description :

Many protocols for adoptive T cell therapy (ACT) include preparative conditioning strategies to deplete host lymphocytes prior to T cell infusion. Total body irradiation and high-dose chemotherapy regimens not only relieve immunosuppression, but increase persistence of the transferred T cells in the host. These preconditioning regimens appear to correlate with improved clinical responses following adoptive T cell therapy. However, they can also result in the death of healthy cells and reduce the quality of life for patients. In addition, some clinical trials employing host conditioning strategies in combination with adoptive T cell transfer have demonstrated tumor persistence and relapse as a result of the outgrowth of antigenic variants. Harnessing endogenous lymphocytes is one method to broaden the tumor-specific T cell repertoire and eliminate tumor cells that have lost the targeted antigen following adoptive T cell therapy. Recent evidence suggests that transferred T cells may eradicate tumors without the need for prior conditioning, indicating that T cell therapies can enhance tumor elimination by relieving immunosuppression and promoting endogenous immunity. Collectively, the data presented in this thesis challenge the popular paradigm that lymphodepleting regimens are crucial for optimal efficacy of all ACTs. NKG2D chimeric antigen receptor (CAR) T cell therapy mounted robust anti-tumor immunity in unconditioned (immune intact) hosts, and this therapy harnessed endogenous macrophage and T cell anti-tumor immunity for superior elimination of ovarian tumors. Moreover, these data suggest that endogenous immunity broadens the specificity of the anti-tumor immune response and is critical for the control of antigenic tumor variants. The data also elucidate unique effector mechanisms employed by the transfused CD8 and CD4+ T cells in awakening endogenous macrophage and T cell immunity. These findings advance the T cell therapy field by improving the understanding of the mechanisms that are required for effective adoptive T cell therapy in unconditioned patients.

Current Perspectives Challenges and Advances in Cell Based Therapies

Current Perspectives  Challenges and Advances in Cell Based Therapies Book
Author : Prashant Trikha,Monica Thakar,Conrad Russell Cruz
Publisher : Frontiers Media SA
Release : 2020-03-24
ISBN : 2889635643
Language : En, Es, Fr & De

GET BOOK

Book Description :

Download Current Perspectives Challenges and Advances in Cell Based Therapies book written by Prashant Trikha,Monica Thakar,Conrad Russell Cruz, available in PDF, EPUB, and Kindle, or read full book online anywhere and anytime. Compatible with any devices.

The Development of Novel T Cell Receptor and Chimeric Antigen Receptor Engineered T Cell Therapies for the Treatment of Cancer

The Development of Novel T Cell Receptor  and Chimeric Antigen Receptor  Engineered T Cell Therapies for the Treatment of Cancer Book
Author : Vanessa Tubb
Publisher : Unknown
Release : 2017
ISBN : 0987650XXX
Language : En, Es, Fr & De

GET BOOK

Book Description :

Download The Development of Novel T Cell Receptor and Chimeric Antigen Receptor Engineered T Cell Therapies for the Treatment of Cancer book written by Vanessa Tubb, available in PDF, EPUB, and Kindle, or read full book online anywhere and anytime. Compatible with any devices.

Cancer Immunotherapy Mechanisms of Cancer Immunity Engineering Immune Based Therapies and Developing Clinical Trials

Cancer Immunotherapy  Mechanisms of Cancer Immunity  Engineering Immune  Based Therapies and Developing Clinical Trials Book
Author : Jianxun Song
Publisher : Bentham Science Publishers
Release : 2015-04-16
ISBN : 1681080486
Language : En, Es, Fr & De

GET BOOK

Book Description :

Clinicians, patients and scientists, alike, have been battling cancer for over several decades; however, patient outcomes have not significantly improved over the years with conventional therapies. In recent years, this has caused researchers to look for a change in the status quo, and, the awareness of the human immune system, which has an intrinsic mechanism to control microbial pathogens and dysfunctional self-tissues, has triggered scientists to look for new modes of cancer therapy. Cancer Immunotherapy has become a major research field as a result of these efforts, gaining some recognition for notable breakthroughs in cancer patient prognosis. Frontiers in Cancer Immunology collectively presents the methods which have been studied and used in cancer immunotherapy based on the different components of human immune system. The series will give clinicians and immunologists a roadmap of current trends in all branches of cancer immunology. This volume lists the major immune system components (such as T cells and NK cells and associated antigens/antibodies) which have been demonstrated to limit the growth of or kill tumor cells. Relevant applications in cancer therapy are also included in addition to a general introduction to engineered as well as targeted cancer immunotherapies (cancer vaccines).

Immunotherapy in Translational Cancer Research

Immunotherapy in Translational Cancer Research Book
Author : Laurence J. N. Cooper,Elizabeth A. Mittendorf,Judy Moyes,Sabitha Prabhakaran
Publisher : John Wiley & Sons
Release : 2018-02-12
ISBN : 1118684524
Language : En, Es, Fr & De

GET BOOK

Book Description :

A guide to state-of-the-art cancer immunotherapy in translational cancer research A volume in the Translational Oncology series, Immunotherapy in Translational Cancer Research explores the recent developments in the role that immunotherapy plays in the treatment of a wide range of cancers. The editors present key concepts, illustrative examples, and suggest alternative strategies in order to achieve individualized targeted therapy. Comprehensive in scope, Immunotherapy in Translational Cancer Research reviews the relevant history, current state, and the future of burgeoning cancer-fighting therapies. The book also includes critical information on drug development, clinical trials, and governmental resources and regulatory issues. Each chapter is created to feature: development of the immunotherapy; challenges that have been overcome in order to scale up and undertake clinical trials; and clinical experience and application of research. This authoritative volume is edited by a team of noted experts from MD Anderson Cancer Center, the world’s foremost cancer research and care center and: Offers a comprehensive presentation of state-of-the-art cancer immunotherapy research that accelerates the pace of clinical cancer care Filled with the concepts, examples, and approaches for developing individualized therapy Explores the breath of treatments that reflect the complexity of the immune system itself Includes contributions from a panel international experts in the field of immunotherapy Designed for physicians, medical students, scientists, pharmaceutical executives, public health and public policy government leaders and community oncologists, this essential resource offers a guide to the bidirectional interaction between laboratory and clinic immunotherapy cancer research.

Evaluation of Reporter Cell Lines Engineered to Express Pertinent CAR T Antigen Targets

Evaluation of Reporter Cell Lines Engineered to Express Pertinent CAR T Antigen Targets Book
Author : Alyssa Coggan
Publisher : Unknown
Release : 2021
ISBN : 0987650XXX
Language : En, Es, Fr & De

GET BOOK

Book Description :

Thermo Fisher Scientific is the world leader in serving science, they aim to make the world healthier, cleaner, and safer place. The company enables its customers to do ground breaking work in the life science industry by accelerating research and bringing treatments to patients. Thermo Fisher Scientific has an extensive product range supporting a wide variety of research areas and workflows, one specific area supported is CAR T-cell therapy research. The products in this area range from cloning systems, lentivirus generation, and advanced genome editing tools for generating CAR T-cells; cellular and molecular characterization platforms and cGMP-grade reagents and medium components. CAR T-cell therapy is a revolutionary immunotherapy whereby patient cells are engineered to fight cancer. This is accomplished by isolating T-cells, engineering cells to express a surface chimeric antigen receptor (CAR), and then placing the cells back into the patient. The CAR recognizes a specific antigen on the cancer cells and attacks the cells, allowing the patient's own immune system to fight the cancer. Currently, CAR T-cell therapy is used to treat patients with specific blood cancers, but it is also being vigorously studied with an eye towards adapting the therapy to treat other types of cancer and solid tumors. As CAR T-cell therapy expands, it is important to ensure the CAR T-cells are safe and effective before putting cells back into the patient. A direct method to measure potency or the effectiveness of the resulting CAR-T cells is by incubating them with target cancer cells and testing their survival rates. Such cytotoxicity assays can be accomplished by measuring lactate dehydrogenase (LDH), an enzyme that is released upon damage to the plasma membrane of cells. The LDH assay, however, is time consuming and laborious when scaled up. Other methods require labeling target cells with reporters such as chromium-51, fluorescent molecules, or luminescent markers. These methods are also time consuming since reporter cell lines need to be generated and optimized prior to use. When cells are labeled with chromium-51 can there is significant background signal and radioactive waste is generated. The goal of this study was to: 1) test previously generated reporter target cell lines, 2) assess the applicability of these cells in cytotoxicity assays, and 3) compare the results to the LDH assay. The target cell lines used express either CD19 (CAR target for B cells) or NGFR (a control), in addition to a GFP (green fluorescent protein) reporter. The cell lines were generated using either lentivirus transduction or Jump-InTM engineering. Target cell lines were validated using antibody staining and flow cytometry to measure GFP, CD19 or NGFR expression. Highest expressing clones were chosen and tested for stability of expression before being used in cytotoxicity assays. Cytotoxicity was measured by the decrease in GFP expression in target cell lines and compared to LDH assay results. Results indicate that the newly generated target cell lines stably express reporters. Cytotoxicity patterns measured by the decrease in GFP expression were comparable to those obtained via the LDH assay. Increasing effector (CAR T) to target (CD19/NGFR) ratios showed increased cytotoxicity, as expected. NGFR cell lines worked as effective controls and show no cytotoxicity, further demonstrating the specificity of CD19 CAR-T cytotoxicity to target CD19 expressing cells. No significant differences were seen in the cytotoxicity values between the lentivirus and Jump-InTM generated cell lines. However, differences were observed between the GFP assays compared to the LDH assay, likely due to lack of a standardized calculation method for the GFP assays. While results using GFP to monitor cytotoxicity are promising, more work needs to be done to better understand how these cell lines perform and to ensure repeatability. Methods for calculating cytotoxicity with GFP need to be refined and additional work to establish a more standardized, accurate measurement system. The initial results from this study are encouraging and warrant further study, particularly in light of how quickly CAR T-cell therapies are advancing.

Engineering VHH based Chimeric Antigen Receptor CAR T Cell Therapy for Solid Tumor Treatment

Engineering VHH based Chimeric Antigen Receptor  CAR  T Cell Therapy for Solid Tumor Treatment Book
Author : Yushu Joy Xie
Publisher : Unknown
Release : 2019
ISBN : 0987650XXX
Language : En, Es, Fr & De

GET BOOK

Book Description :

Chimeric antigen receptor (CAR) T cells are a promising cancer therapeutic, as they can specifically redirect the cytotoxic function of a T cell to a chosen target of interest. CAR T cells have been successful in clinical trials against hematological cancers, but have experienced low efficacy against solid tumors for a number of reasons, including a paucity of tumor-specific antigens to target and a highly immunosuppressive solid tumor microenvironment. In chapter 2 of this thesis, we develop a strategy to target multiple solid tumor types through markers in their microenvironment. The use of single domain antibody (VHH)-based CAR T cells that recognize these markers circumvents the need for tumor-specific targets. Chapter 3 will describe methods to overcome the immunosuppressive microenvironment of solid tumors. Here, we have developed VHH-secreting CAR T cells that can modulate additional aspects of the tumor microenvironment, including the engagement of the innate immune system through secretion of a VHH against an inhibitor of phagocytosis. We show that this strategy of VHH-secretion by CAR T cells can lead to significant benefits in outcome. We also demonstrate that delivery of therapeutics by CAR T cells can improve the safety profile of the therapeutic. Chapter 4 of this thesis explores strategies to increase the targeting capacity of CAR T cells by building logic-gated CARs. Finally, chapter 5 will describe work in imaging CAR T cells specifically, longitudinally, and non-invasively through PET imaging. Our results demonstrate the flexibility of VHHs in CAR T cell engineering and the potential of VHH-based CAR T cells to target the tumor microenvironment, modulate the tumor microenvironment, and treat solid tumors.

Heat Inducible Chimeric Antigen Receptor CAR T Cell for Prostate Cancer Therapy

Heat Inducible Chimeric Antigen Receptor  CAR  T Cell for Prostate Cancer Therapy Book
Author : Xin Wang
Publisher : Unknown
Release : 2019
ISBN : 0987650XXX
Language : En, Es, Fr & De

GET BOOK

Book Description :

While chimeric antigen receptor (CAR) therapy has emerged as a promising method for cancer therapy by engineering autologous T cells to redirect them to the specific tumor-associate antigen and kill the tumor cells, these engineered T cells also have "on-target, off-tumor" toxicity, which can harm normal tissues and can be life-threatening. The non-specific activity inspires us to control CAR expression with high spatiotemporal precisions. Therefore, we present the design of heat inducible CAR, which can upregulate CAR expression after heat stimulation. The thesis introduces the study of heat inducible anti-prostate specific membrane antigen (PSMA) CAR T cells, which has been proved to be able to sense heat and produce CARs for the targeting of prostate cancer cells and triggering activation of T cells. The study can serve as a foundation for broader application in solid tumor therapy.

Defects in T Cell Trafficking and Resistance to Cancer Immunotherapy

Defects in T Cell Trafficking and Resistance to Cancer Immunotherapy Book
Author : Emmanuel Donnadieu
Publisher : Springer
Release : 2016-08-30
ISBN : 3319422235
Language : En, Es, Fr & De

GET BOOK

Book Description :

This volume focuses on recent advances in understanding T cells as key players in antitumor immune responses, and as a result T cell-based immunotherapy is starting to transform the treatment of advanced cancers. However, despite recent successes, many patients with cancer fail to respond to these treatments. Defective migration of T cells into and within tumors is considered as an important resistance mechanism to cancer immunotherapy.The volume includes three sections. The first section covers general knowledge about T cell trafficking during a normal immune response but also during tumor development. The second section provides an in-depth description of the different obstacles that prevent T cells from migrating and contacting tumor cells. The third section explores therapeutic strategies to improve trafficking of T cells into tumors and, thus, to enhance the effectiveness of cancer immunotherapy.